TriSalus Life Sciences Makes Significant Strides in Cancer Treatment
TriSalus Life Sciences®, Inc. (Nasdaq: TLSI) is making impressive advancements in cancer treatment, particularly by improving the way therapies target liver and pancreatic tumors. Their innovative Pressure-Enabled Drug Delivery™ (PEDD™) technique, implemented through the TriNav® Infusion System, has recently shown promising results that surpass conventional methods. A key study published in the Journal of Vascular and Interventional Radiology highlights how effective the PEDD technique is in allowing greater penetration of glass microspheres (GM) into solid tumors.
Key Findings of the Study
The research, titled “Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model,” demonstrates substantial improvements in how treatments are delivered. Conducted on transgenic pigs, the study found that the PEDD method not only increased the delivery of glass microspheres but also enabled more precise targeting of tumor tissues compared to traditional microcatheter methods.
Dr. Bryan F. Cox, TriSalus's Chief of Research, expressed his enthusiasm about the results, stating, “This is another example of how our PEDD approach effectively addresses a major challenge in cancer care, ensuring more selective and increased delivery of therapeutics to tumors.” The research not only reflects enhanced delivery rates but also opens up possibilities for more strategic treatment approaches aimed at targeting multiple tumors in patients facing significant disease burdens.
Improving Safety and Effectiveness
Mary Szela, TriSalus's CEO, underscored the meaningful enhancements brought about by the PEDD method. She noted, “Efficiently delivering therapeutics directly into tumor cells, without harming the surrounding healthy tissue, remains a major challenge in cancer care, and the PEDD approach aims to address this issue.” This improved technique offers hope to patients struggling with complex liver and pancreatic tumors, emphasizing the vital role of innovative approaches in today’s medical landscape.
Moreover, the study suggests that the new PEDD technique might match the safety profile seen in selective Y90 treatments, typically used for more advanced diffuse disease cases. This development means that it may be possible to achieve effective treatment outcomes without compromising patient safety, which is a significant step toward better cancer management strategies.
Research Overview and Insights
The research involved evaluating transgenic pigs and assessing how different infusion techniques impacted tumor treatment delivery. By using near-infrared imaging to detect fluorescent signals from the glass microspheres, the results indicated a 117% increase in tumor penetration when utilizing lobar infusions via the PEDD method, with a 39% improvement noted for selective infusions. These findings serve as compelling evidence of enhanced delivery while underscoring the importance of innovation in overcoming major hurdles in cancer therapy.
It is particularly noteworthy that the lobar PEDD delivery of glass microspheres was statistically comparable to traditional selective delivery methods, marking a significant advancement in treatment approaches.
About TriSalus Life Sciences
TriSalus Life Sciences® is at the forefront of developing drug delivery technologies that aim to revolutionize how liver and pancreatic cancers are treated. Their innovative platform includes advanced systems like the TriNav® Infusion System, which utilizes PEDD to boost therapy delivery while reducing damage to healthy tissues. TriSalus's commitment to innovation shines through its collaborations with leading cancer centers nationwide, driving advancements in medical technology and improving patient outcomes.
In addition to their ongoing developments, TriSalus is working with an investigational immunotherapy candidate, nelitolimod, which aims to tackle the immunosuppressive environments created by tumors that often diminish the effectiveness of existing therapies. Their clinical trials are showing promising preliminary results, indicating that using nelitolimod alongside PEDD might help overcome delivery challenges within the complex anatomy of the liver and pancreas.
TriSalus is dedicated to making significant improvements in patient care through the proactive development of their therapies, demonstrating a profound commitment to advancing oncology.
Frequently Asked Questions
What is the PEDD method?
The Pressure-Enabled Drug Delivery (PEDD) method improves the delivery of treatments by adjusting pressure and flow, allowing deeper penetration into tumors while protecting the surrounding healthy tissues.
How does the TriNav® Infusion System work?
The TriNav® Infusion System is equipped to optimize drug delivery to liver tumors, employing the PEDD technique for effective treatment outcomes.
What were the main results of the recent research study?
The study highlighted significant improvements in glass microsphere penetration into liver tumors, showing a 117% increase with lobar infusions using the PEDD method compared to standard techniques.
Who benefits from these advancements?
Patients affected by liver and pancreatic tumors are likely to benefit greatly from the improved effectiveness and safety profiles associated with TriSalus Life Sciences' innovative delivery methods.
What goals does TriSalus Life Sciences strive to accomplish?
TriSalus is committed to enhancing drug delivery systems in cancer treatment, improving patient outcomes, and advancing research to tackle challenges faced in tumor therapy.
